
Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer
There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.





























